2 March 2020 |
AIM: RENE |
("ReNeuron" or the "Company")
Block Listing Review and Total Voting Rights
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements.
|
Name: |
ReNeuron Group plc |
|
Name of Scheme: |
ReNeuron Share Option Schemes |
|
Period of Return: |
From 1 September 2019 to 29 February 2020 |
|
Balance of unallotted securities under scheme(s) from previous return: |
716,741 Ordinary Shares (of 1p each)
|
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last Review (if any increase has been applied for): |
N/A |
|
Less: Number of securities issued/allotted under scheme(s) during period |
1,500 |
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
715,241 Ordinary Shares |
|
Number and class of securities originally admitted and the date of admission: |
20,000 ordinary shares on 13 May 2010 |
Total Voting Rights
At 29 February 2020, the Company had 31,833,770 Ordinary Shares in issue, all with voting rights. The Company holds no Ordinary Shares in treasury. The figure of 31,833,770 Ordinary Shares may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.
ENDS
ENQUIRIES:
|
Contacts:
ReNeuron |
+44 (0) 20 3819 8400 |
|
Olav Hellebø, Chief Executive Officer |
|
|
Michael Hunt, Chief Financial Officer |
|
|
Buchanan (UK Media/Investor Relations) |
+44 (0) 20 7466 5000 |
|
Mark Court, Tilly Abraham |
|
|
Argot Partners (US Media/Investor Relations) Claudia Styslinger, David Rosen |
+1 212 600 1902 |
|
|
|
|
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker) Jonathan Senior, Stewart Wallace, Ben Maddison |
+44 (0) 20 7710 7600
|
|
N+1 Singer (Joint Broker) Aubrey Powell, James Moat, Tom Salvesen |
+44 (0) 20 7496 3000 |
|
|
|
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.
